Tetrocarcin-A—induced ER stress mediates apoptosis in B-CLL cells via a Bcl-2—independent pathway
- 1 June 2003
- journal article
- Published by American Society of Hematology in Blood
- Vol. 101 (11) , 4561-4568
- https://doi.org/10.1182/blood-2002-08-2501
Abstract
Tetrocarcin-A (TC-A), an antibiotic agent isolated from actinomycetes, has recently been described to antagonize Bcl-2 functions, thereby sensitizing tumor cells to cell death signals under control of Bcl-2. In this study, we analyzed the direct proapoptotic effect of TC-A in the B-chronic lymphocytic leukemia (B-CLL) model. We focused on the signal cascade triggered by TC-A in B-CLL cells and identified activated mitochondrial as well as endoplasmatic reticulum (ER) stress signals. The expression levels of known effector molecules mediating mitochondrial signaling, such as Bax and Bid, and the antagonistic molecule Bcl-2 did not influence sensitivity of B-CLL cells to TC-A. Furthermore, the molecular chaperone and sensor of ER stress, HSP70, though significantly up-regulated in B-CLL cells undergoing TC-A—triggered apoptosis, was ineffective to exert its anti-apoptotic function described in multiple cell death pathways. Autologous T cells of B-CLL patients were significantly less sensitive to TC-A as were also T cells from healthy donors when compared with their normal B-cell fraction. Furthermore, sensitivity of B-CLL cells to TC-A treatment in vitro was dependent neither on the expression levels of CD38—a prognostic factor for survival of B-CLL patients as well as for their response to therapy—nor on the clinical stage or pretreatment status of patients. From our data showing that TC-A induced a cell death pathway via ER stress preferentially in B cells and that it acted independently of important markers of drug sensitivity and of clinical markers, we conclude that TC-A might represent an attractive candidate drug for further evaluation in preclinical trials.Keywords
This publication has 50 references indexed in Scilit:
- Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemiaLeukemia, 2002
- Cladribine in the Treatment of Chronic Lymphocytic LeukemiaLeukemia & Lymphoma, 2001
- Infectious complications in chronic lymphocytic leukaemia.Hematology and Cell Therapy, 1999
- Long-Term Follow-Up of Patients With Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine Regimens as Initial TherapyBlood, 1998
- p53 Expression in B-Cell Chronic Lymphocytic Leukemia: A Marker of Disease Progression and Poor PrognosisBlood, 1998
- bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemiaBlood, 1993
- Second Cancers in patients With Chronic Lymphocytic LeukemiaJNCI Journal of the National Cancer Institute, 1992
- T-cell activation and subset patterns are altered in B-CLL and correlate with the stage of the diseaseBlood, 1989
- Analysis of T‐cell subsets in B‐cell chronic lymphocytic leukemia: A correlation with the stage of diseaseAmerican Journal of Hematology, 1984
- Abnormal T-cell subpopulation function in CLL: excessive suppressor (T gamma) and deficient helper (T mu) activity with respect to B-cell proliferationBlood, 1981